Enzon Pharmaceuticals, Inc. Commences Enrollment of Two Phase 1 Studies of PEG-SN38 for Advanced Solid Tumors and Lymphoma

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that several patients have been enrolled in two Phase 1 studies of PEG-SN38 (EZN-2208), Enzon’s PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection). These studies are designed to evaluate the safety, tolerability, and pharmacokinetics of PEG-SN38 in different dosing schedules for patients with advanced solid tumors or lymphoma.